Consensus Guidelines for NGS in Sarcoma Diagnosis and Treatment
A consensus statement concludes that while next-generation sequencing (NGS) holds great promise for identifying 'tumor-agnostic' therapies, evidence does not support its routine use in clinical care and diagnosis of sarcoma.
Sarcomas are a heterogeneous group of malignancies, with over 70 distinct histologic subtypes and numerous ultrarare entities, but generally exhibit a low mutational burden, complicating precision oncology approaches.
- Sarcomas represent one of the most heterogeneous groups of malignancies.
- NGS has become widely available, raising questions about its role in sarcoma diagnosis and treatment.
Next-generation sequencing (NGS) holds great promise for identifying 'tumor-agnostic' therapies.
Author's summary: NGS not recommended for routine sarcoma diagnosis.
More News
- Nigeria: Rotary Boosts Maternal, Child Health Drive in Nigeria With $5m Funding
- Nasarawa Amazons Chairperson dedicates SWAN Honour to Gov. Sule, club - The Nation Newspaper
- National Day against Global Arrogance Marked in Iran - Politics news - Tasnim News Agency
- Dangote on my mind (VI) - The Nation Newspaper
- Artist Bianca Broxton returns to Medford to remember Belinda Sutton, an enslaved woman, for the 250th anniversary of the American Revolution - The Tufts Daily
- I joined APC to save Bayelsa from sinking - Diri | The ICIR- Latest News, Politics, Governance, Elections, Investigation, Factcheck, Covid-19
- The MIAA’s Continued, and Growing, CM Problem | WATD 95.9 FM